Christie M. Ballantyne, MD

View Faculty Disclosure Statement

Director, Center for Cardiovascular Disease Prevention
Methodist DeBakey Heart Center
Codirector, Lipid Metabolism and Atherosclerosis Clinic
The Methodist Hospital
Associate Chief and Clinical Director
Section of Atherosclerosis, Department of Mediciine
Director, Maria and Alando J. Ballantyne Atherosclerosis and Lipid Laboratory
Professor of Medicine and Pediatrics
Baylor College of Medicine
Houston, Texas

Biographical Sketch

Christie M. Ballantyne, MD, is director of the Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, and codirector of the Lipid Metabolism and Atherosclerosis Clinic, The Methodist Hospital, Houston, Texas. He is also associate chief and clinical director of the Section of Atherosclerosis, Department of Medicine; director of the Maria and Alando J. Ballantyne, MD, Atherosclerosis Laboratory; and professor of medicine and pediatrics, Baylor College of Medicine, Houston. He received an MD degree from Baylor College of Medicine, and his postgraduate training included an internal medicine residency at University of Texas Southwestern Medical School, Dallas, Texas; a cardiology fellowship at Baylor College of Medicine; and an American Heart Association/Bugher Foundation Fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor.

Dr. Ballantyne has been the recipient of numerous study grants, including an American Heart Association Established Investigator Award, and has several National Institutes of Health grants to study leukocyte–endothelial adhesion molecules and novel markers for atherosclerosis. He is editorial director for www.lipidsonline.org. Dr. Ballantyne has published extensively and has spoken nationally and internationally on lipids, atherosclerosis, and inflammation. Dr. Ballantyne's research interests include the pathophysiology of atherosclerosis, with an emphasis on monocyte activation and adhesion.

Faculty Disclosure Statement

Dr. Ballantyne has disclosed that he has received grants and research support from AstraZeneca Pharmaceuticals LP; diaDexus, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Reliant Pharmaceuticals; Schering-Plough Corporation; Sanofi-Synthelabo; and Kos Pharmaceuticals, Inc.  He has also served as a consultant for AstraZeneca Pharmaceuticals LP; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Reliant Pharmaceuticals; Schering-Plough Corporation; and Bayer and has participated in Speakers Bureau activities for AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Kos Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Reliant Pharmaceuticals; Sanofi-Synthelabo, Inc.; and Schering-Plough Corporation.